Compare
Entyvio vs. Skyrizi

Entyvio, the brand name for vedolizumab, is an injection used to treat ulcerative colitis (UC) and Crohn's disease (CD) in adults. It belongs to a drug class called integrin antagonists that helps lower inflammation in the gut. Entyvio (vedolizumab) is an infusion that's given through the vein by a healthcare professional. After the first 2 doses, it's usually given every 2 months. If it works well, people can switch to injections under the skin every 2 weeks using prefilled syringes or pens. Side effects include headache, mild infections, and joint pain.

• Moderate-to-severe ulcerative colitis (UC) in adults
• Moderate-to-severe Crohn's disease (CD) in adults

• Infection in nose and throat (13%)
• Headache (12%)
• Joint pain (12%)
• Nausea (9%)
• Fever (9%)
• Upper respiratory tract infection (7%)
• Fatigue (6%)
• Cough (5%)

• Infusion-related reactions and allergic reactions
• Risk of serious infections
• Risk of brain infection (progressive multifocal leukoencephalopathy)
• Liver problems

Skyrizi (risankizumab or risankizumab-rzaa) is an injection used to treat different inflammatory conditions in adults. This includes plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It belongs to the drug class called interleukin antagonists. It works to lower inflammation and relieve symptoms. After the first few doses, you usually get the Skyrizi (risankizumab) injection every 2 or 3 months. This medication can raise your risk of infection as a side effect.

• Moderate-to-severe plaque psoriasis in adults
• Psoriatic arthritis in adults
• Moderate-to-severe Crohn's disease in adults
• Moderate-to-severe ulcerative colitis in adults

• Upper respiratory infections (13%)
• Headache (4%)
• Tiredness (3%)

• Allergic reaction
• Risk of infection
• Rare case of liver injury
• Caution when getting vaccines